Autologous cell therapy for the regeneration of skeletal muscle tissue

Muvon Therapeutics is pioneering a therapeutic platform focused on the regeneration of skeletal muscle tissue, utilizing autologous muscle precursor cells (MPCs) derived from the patient's own muscle tissue. The process begins with a minimally invasive biopsy, from which MPCs are isolated and expanded under controlled conditions. Once a sufficient number of cells is obtained, they undergo rigorous quality control before being injected into the damaged muscle. This innovative approach not only aims to repair damaged tissue but also enhances the regenerative capacity of weakened muscles, addressing conditions such as stress urinary incontinence in women.

The technology developed by Muvon Therapeutics emphasizes functional regeneration without the use of genetic modifications or synthetic materials, making it a low-risk option based on initial clinical results. The company's vision is to establish personalized regenerative treatments as a standard of care for patients suffering from debilitating muscle-related diseases, ultimately extending the human healthspan. By focusing on the body's natural regenerative capabilities, Muvon aims to provide effective solutions for a range of conditions associated with muscle damage and degradation.

Switzerland

MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.

Muvon Therapeutics

Company Details